Growing up bipolar: ‘Nobody was on my side’

Jennifer Konjoian was 10 years old when she put a plastic bag over her head. She remembers doing it impulsively, for no other reason than to get attention.

Forest Laboratories, Inc. And Gedeon Richter Plc Announce Results From A Phase II Study Of Cariprazine For The …

Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc. today announced preliminary top-line results from an 8-week Phase II clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of bipolar depression. Cariprazine is currently undergoing Phase III trials for separate indications of schizophrenia and bipolar mania. A total of 233 patients were …

Are mood swings a sign of depression?

Is it possible to have mood swings where one moment you are happy, then the next you can be sad? Is this a sign of depression? I do also have ADD as well but currently am not on medicine.

‘Lovable guy’ was bipolar, family says of Visalia shooter from Modesto

Family members describe two sides of 47-year-old Kenneth James Ward of Modesto. He was a veteran of the Persian Gulf War, a doting father to his 6-year-old son and a lovable brother to his siblings.

Naurex announces GLYX-13 molecule recognized in “Top 10 to Watch” list for depression treatment

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that its clinical stage candidate for the treatment of depression, GLYX-13, and its second-generation NRX-1050 series have been selected for inclusion on Windhover’s list of the “Top 10 Most Interesting Neuroscience Projects to Watch.”

Courses help relatives deal with mental illness

The National Alliance on Mental Illness and Recovery Marin will offer a free, comprehensive 12-week course designed specifically for families of persons with major depression, bipolar disorder, schizophrenia, panic disorder, obsessive compulsive disorder and other severe mental illnesses.

Forest, Gedeon say drug fails midstage study

Forest Laboratories Inc. and Gedeon Richter PLC said Monday their potential bipolar depression treatment cariprazine did non meet key goals in a midstage study.

Latest achievements in brain research and treatment for mental disorders

Mental disorders, such as depression, anxiety disorders, addiction and schizophrenia are the core challenge of most health care systems around the world. In the EU alone, each year 27% of the total adult population – this corresponds to 83 Million citizens – suffer from mental disorders. Depression alone affects almost 20 million ranking in the EU as the most disabling disorder of all diseases.

Richter, Forest Laboratories consider further Phase II testing of cariprazine for depression

Hungarian pharmaceutical company Gedeon Richter and its US partner Forest Laboratories announced on Monday that they are considering further Phase II dose-effect testing of their new investigational antipsychotic agent cariprazine based on the preliminary results of Phase II clinical trials of cariprazine for the treatment of bipolar depression.

Circadian rhythms: Their role and dysfunction in affective disorder

( European College of Neuropsychopharmacology ) Biological clocks play a major role in affective disorders. Synchronizing impaired circadian rhythms, improving sleep, or paradoxically staying awake most of the night can be extremely helpful to treat patients with depression and bipolar disorder. Chronotherapeutic combinations of light and wake therapy achieve fast results and also minimize …

Next Page »